Gräf, Markus http://orcid.org/0000-0002-8468-2349
Knitza, Johannes http://orcid.org/0000-0001-9695-0657
Leipe, Jan http://orcid.org/0000-0001-9684-9700
Krusche, Martin http://orcid.org/0000-0002-0582-7790
Welcker, Martin http://orcid.org/0000-0002-1856-3085
Kuhn, Sebastian http://orcid.org/0000-0002-8031-2973
Mucke, Johanna http://orcid.org/0000-0001-8915-7837
Hueber, Axel J. http://orcid.org/0000-0001-6454-1234
Hornig, Johannes http://orcid.org/0000-0001-9875-9610
Klemm, Philipp http://orcid.org/0000-0001-7911-4235
Kleinert, Stefan http://orcid.org/0000-0002-2588-7547
Aries, Peer http://orcid.org/0000-0001-7919-8010
Vuillerme, Nicolas http://orcid.org/0000-0003-3773-393X
Simon, David http://orcid.org/0000-0001-8310-7820
Kleyer, Arnd http://orcid.org/0000-0002-2026-7728
Schett, Georg http://orcid.org/0000-0001-8740-9615
Callhoff, Johanna http://orcid.org/0000-0002-3923-2728
Funding for this research was provided by:
Novartis Pharma (33419272)
Deutsche Forschungsgemeinschaft (2886)
Universitätsklinikum Erlangen
Article History
Received: 19 July 2022
Accepted: 29 August 2022
First Online: 10 September 2022
Declarations
:
: JK has received research support from Novartis Pharma GmbH. SK and MW are members of RheumaDatenRhePort. JK is a member of the scientific board of RheumaDatenRhePort.
: The study was approved by the ethics committee of the medical faculty of the university of Erlangen-Nürnberg, Germany (106_19 Bc), approved 23rd July 2019. Informed consent was obtained from all subjects involved in the study. Written informed consent has been obtained from the patients to publish this paper.